8-K: Theriva Biologics Files Prospectus Supplement for Up to $2.5 Million At-The-Market Stock Offering

Theriva Biologics, Inc. has filed a prospectus supplement to offer and sell up to $2,534,352 of its common stock through an at-the-market offering facility.

Summary

• Theriva Biologics, Inc. (the "Company") filed a prospectus supplement on June 20, 2025, related to its Registration Statement on Form S-3.
• The filing enables the offer and sale of up to $2,534,352 of the Company's common stock.
• Sales will be conducted "at the market" through A.G.P./Alliance Global Partners (the "Sales Agent").
• The Sales Agent will receive a commission rate of up to 3.0% of the gross sales price per share sold.
• The offering is pursuant to an Amended and Restated At Market Issuance Sales Agreement, originally dated February 9, 2021, and subsequently amended on May 3, 2021, and May 2, 2024.

Sentiment

Score: 6

Explanation: The filing indicates a standard, flexible capital raising mechanism, which is generally positive for a company's liquidity and operational flexibility, though it carries the inherent negative of potential shareholder dilution.

Positives

• Provides a flexible mechanism for the Company to raise capital as needed, without the requirement for a large, single underwritten offering.
• Leverages an existing and previously established "at-the-market" sales agreement, indicating a streamlined process for capital access.
• The capital raise can support ongoing operations, research and development, or strategic initiatives, enhancing the Company's financial flexibility.

Negatives

• Potential for dilution of existing shareholders as new shares are issued into the market.
• The actual amount of capital raised is uncertain and depends on market conditions and the Sales Agent's efforts, introducing variability in funding.
• Sales Agent compensation of up to 3.0% of gross sales will reduce the net proceeds received by the Company from the offering.

Risks

• Share Dilution: The issuance of new common stock will dilute the ownership percentage and potentially the earnings per share of current shareholders.
• Market Price Volatility: The price at which shares can be sold under the ATM offering is subject to market fluctuations, which could impact the total amount of capital raised and the average price per share.
• Sales Agent Performance: The Sales Agent is not obligated to sell any specific amount of shares, and sales depend on their "commercially reasonable efforts," meaning the Company may not raise the full target amount.

Future Outlook

The Company intends to offer and sell shares of common stock from time to time through the Sales Agent, indicating an ongoing capital raising strategy dependent on market conditions and funding needs.

Management Comments

• The report was signed by Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer, indicating management's authorization and oversight of the filing and the underlying capital raising strategy.

Industry Context

At-the-market (ATM) offerings are a common financing tool for smaller public companies, particularly in the biotechnology sector, to raise capital incrementally and flexibly without the need for a large, single underwritten offering. This method allows companies to access capital as needed, often at prevailing market prices, which can be advantageous for companies with fluctuating capital requirements or those seeking to minimize upfront financing costs.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new common stock, which could impact per-share metrics.
• Company: Enhanced financial flexibility and access to capital for ongoing operations, research, and strategic initiatives, supporting long-term viability.

Next Steps

• The Company may sell shares of common stock from time to time through the Sales Agent under the terms of the Sales Agreement, subject to market conditions and the Company's capital needs.

Key Dates

Keywords

Theriva Biologics, TOVX, at-the-market offering, ATM, capital raise, common stock, prospectus supplement, SEC filing, equity financing, biotechnology, biopharma